SK Bioscience Undertakes Overseas Business Organization Restructuring

[Asia Economy Reporter Chunhee Lee] SK Bioscience has carried out an organizational restructuring to advance its global business.

On the 1st, SK Bioscience announced that it expanded and reorganized its existing Overseas Business Development Office into BD Offices 1 to 3, and established a new Global Regulatory Affairs (Global RA) Office dedicated to global regulation and approval.

SK Bioscience emerged as a global vaccine company through COVID-19 vaccine contract development and manufacturing (CDMO) during the COVID-19 pandemic. As its global business scope and scale rapidly grew, the company expanded and reorganized the existing dedicated Overseas Business Development Office into BD Offices 1 to 3 to further subdivide and specialize the organization accordingly. The BD Offices 1 to 3 will be responsible for enhancing and executing various areas of global business, including not only the existing vaccine business but also new businesses such as cell and gene therapy (CGT), joint development with global networks, new C(D)MO contract acquisition, and commercialization of developed products.

Additionally, by establishing the Global RA Office, SK Bioscience plans to accelerate the acquisition of international-level certifications and approvals, such as GMP (Good Manufacturing Practice) certification in advanced countries like the United States and Europe.

The CMC team was also newly established. CMC stands for Chemistry, Manufacturing, and Control, playing a key role in process development and quality control (QC) for finished pharmaceutical products (DP). It manages all GMP-related tasks from research to clinical trials, approval, production, and quality.

An SK Bioscience official stated, "This organizational restructuring will further accelerate our growth into a global top-tier bio company and serve as an opportunity to secure a super-gap competitive edge."

This content was produced with the assistance of AI translation services.